Mortality and years of life lost of colorectal cancer in China, 2005-2020: findings from the nationa

来源 :中华医学杂志英文版 | 被引量 : 0次 | 上传用户:cjrck
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background::Colorectal cancer (CRC) is the fourth cause of cancer death in China. We aimed to provide national and subnational estimates and changes of CRC premature mortality burden during 2005-2020.Methods::Data from multi-source on the basis of the national surveillance mortality system were used to estimate mortality and years of life lost (YLL) of CRC in the Chinese population during 2005-2020. Estimates were generated and compared for 31 provincial-level administrative divisions in China.Results::Estimated CRC deaths increased from 111.41 thousand in 2005 to 178.02 thousand in 2020; age-standardized mortality rate decreased from 10.01 per 100,000 in 2005 to 9.68 per 100,000 in 2020. Substantial reduction in CRC premature mortality burden, as measured by age-standardized YLL rate, was observed with a reduction of 10.20% nationwide. Marked differences were observed in the geographical patterns of provincial units, and they appeared to be obvious in areas with higher economic development. Population aging was the dominant driver which contributed to the increase in CRC deaths, followed by population growth and age-specific mortality change.Conclusions::Substantial discrepancies were observed in the premature mortality burden of CRC across China. Targeted considerations were needed to promote a healthy lifestyle, expand cost-effective CRC early screening and diagnosis, and improve medical treatment to reduce CRC mortality among high-risk populations and regions with inadequate healthcare resources.“,”Background::Colorectal cancer (CRC) is the fourth cause of cancer death in China. We aimed to provide national and subnational estimates and changes of CRC premature mortality burden during 2005-2020.Methods::Data from multi-source on the basis of the national surveillance mortality system were used to estimate mortality and years of life lost (YLL) of CRC in the Chinese population during 2005-2020. Estimates were generated and compared for 31 provincial-level administrative divisions in China.Results::Estimated CRC deaths increased from 111.41 thousand in 2005 to 178.02 thousand in 2020; age-standardized mortality rate decreased from 10.01 per 100,000 in 2005 to 9.68 per 100,000 in 2020. Substantial reduction in CRC premature mortality burden, as measured by age-standardized YLL rate, was observed with a reduction of 10.20% nationwide. Marked differences were observed in the geographical patterns of provincial units, and they appeared to be obvious in areas with higher economic development. Population aging was the dominant driver which contributed to the increase in CRC deaths, followed by population growth and age-specific mortality change.Conclusions::Substantial discrepancies were observed in the premature mortality burden of CRC across China. Targeted considerations were needed to promote a healthy lifestyle, expand cost-effective CRC early screening and diagnosis, and improve medical treatment to reduce CRC mortality among high-risk populations and regions with inadequate healthcare resources.
其他文献
肝细胞癌腹腔淋巴结转移患者术后复发快,整体预后差。本文通过回顾性分析郑州大学附属肿瘤医院肝胆胰腺外科2014年8月至2019年8月手术治疗的37例肝细胞癌腹腔淋巴结转移患者临床资料,分析患者肝肿瘤大小、转移淋巴结数目及分布、手术治疗方式等对患者生存及预后的影响。结果表明肝细胞癌淋巴结转移患者整体预后差,单发淋巴结转移患者手术后可延长患者生存期,多发淋巴结转移患者术后易短期内复发、转移,术后生存时间
目的探讨Q-box手动描绘模式超声剪切波弹性成像(shear wave elastography,SWE)预测乳腺癌新辅助化疗病理反应性的临床价值。方法收集福建省肿瘤医院2019年8月至2020年9月接受新辅助化疗的患者56例,根据术后病理Miller&Payne分级(G1~G5)分为反应组(G4~G5)和非反应组(G1~G3)。在化疗前及化疗2、4周期末行常规超声和SWE检查,获得肿瘤最大径的变
目的分析风湿性疾病合并纵隔气肿的临床特点和相关风险因素。方法回顾性分析北京协和医院与山西白求恩医院1998年1月至2018年10月风湿性疾病合并纵隔气肿的住院患者临床资料,患者分为炎性肌病组(IIM)和非炎性肌病组(non-IIM),比较2组患者的临床特点、实验室检查和治疗的区别,应用Cox风险比例模型分析风湿性疾病合并纵隔气肿死亡的风险因素。结果共纳入94例,男性45例(占48%),平均年龄(4
目的探索宫颈癌及子宫内膜癌患者肠道微生物与放疗期间放射性肠炎的严重程度的关系。方法收集37例宫颈癌和子宫内膜癌接受放射治疗的患者粪便样本。包括根治性放疗(RR)和术后放疗(PR)患者。根据CTCAE 5.0中腹泻和直肠炎的级别记录症状,任何症状2级及以上记为高症状级别(HG),否则记为低症状级别(LG)。用16S rRNA测序方法对粪便样本的DNA进行测序及生物统计分析,分析指标包括α多样性、β多
原发性肝癌(肝癌)是严重危害人类健康的常见恶性肿瘤。在全球范围内的发病率位居第5,也是第3位的癌性致死病因[1]世界上肝癌发病率最高的地区是亚洲和非洲,肝癌是中国第二大最常见的恶性肿瘤,每年约383000人死于肝癌,占世界上因肝癌死亡人数的51%[2,3]。肝癌主要包括肝细胞癌(HCC)、肝内胆管细胞癌(ICC)和混合型3种不同病理类型,其中HCC最常见,在全球范围内HCC约占所有肝癌的75%,ICC占12%-15%,混合型最少见[4]
随着吲哚菁绿(ICG)荧光成像技术近年来在腹腔镜肝切除中的应用,术中肝肿瘤切缘及肝段边界高度可视化成为可能。然而,尽管该技术在肝肿瘤手术领域中应用已渐趋成熟,其荧光成像质量相关的影响因素仍未完全明确。本文综述了现有肝切除ICG染色相关文献,分析总结了ICG给药方案、成像获取、患者肿瘤特性及术前肝功能指标等不同因素对术中ICG成像质量的影响,以期为临床及相关研究提供参考。
目的探讨原发性肝癌(肝癌)术后复发补救性肝移植(SLT)疗效及预后影响因素。方法回顾性分析2014年5月至2019年10月在复旦大学附属华山医院行肝移植的273例肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男252例,女21例;平均年龄(51±9)岁。根据术式不同分组,行初始肝移植(PLT)196例(PLT组),肝癌根治性切除后复发行SLT 77例(SLT组)。比较两组围手术期和并发症发生情况。生存分析采用Kaplan-Meier法和Log-rank检验。采用Cox比例风险回归模型分析
目的探讨早期结外鼻型NK/T细胞淋巴瘤放化疗综合治疗的疗效及不良反应。方法回顾性分析本院收治的174例经病理证实的结外鼻型NK/T细胞淋巴瘤患者资料。生存分析及组间比较采用Kaplan-Meier法和Log-rank检验。结果全组Ⅰ期患者102例,Ⅱ期患者72例。2例患者接受单纯放疗,172例患者接受放化疗综合治疗。全组总有效率为94.2%(164/174),其中完全缓解(CR)患者153例(87
肝门部胆管癌是起源于起源于左肝管、右肝管、肝总管以及三者汇合区的恶性肿瘤。Gerald Klatskin于1965年首先在American Journal of Medicine报道,故又称Klatskin瘤[1]。肝门部胆管癌占胆管癌的50%-70%,总体发病率较低,但预后较差。外科手术切除是目前肝门部胆管癌唯一有效的治疗手段,对肝门部胆管癌进行规范化诊治有助于提高患者生存率[2-4]
目的观察电离辐射对小鼠耳蜗带状突触损伤情况,并探讨α-硫辛酸(LA)对其的保护作用。方法随机区组法将小鼠分为健康对照组、照射3 d组、照射3 d+LA组、照射14 d组和照射14 d+LA组,每组10只。各照射组使用辐照仪进行16 Gy X射线照射;照射+LA组,照射后给予LA每日1次;健康对照组给予等量生理盐水。所有小鼠在照射和处死前行听性脑干反应(ABR)测试。免疫荧光标记蛋白ctBP2,观察